These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 25922063)

  • 21. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital.
    Choi YL; Sun JM; Cho J; Rampal S; Han J; Parasuraman B; Guallar E; Lee G; Lee J; Shim YM
    PLoS One; 2013; 8(2):e56011. PubMed ID: 23468851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.
    Zer A; Moskovitz M; Hwang DM; Hershko-Klement A; Fridel L; Korpanty GJ; Dudnik E; Peled N; Shochat T; Leighl NB; Liu G; Feld R; Burkes R; Wollner M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2017 Mar; 18(2):156-161. PubMed ID: 27913214
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
    Cheng Y; Murakami H; Yang PC; He J; Nakagawa K; Kang JH; Kim JH; Wang X; Enatsu S; Puri T; Orlando M; Yang JC
    J Clin Oncol; 2016 Sep; 34(27):3258-66. PubMed ID: 27507876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
    Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
    J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience.
    Tokaca N; Barth S; O'Brien M; Bhosle J; Fotiadis N; Wotherspoon A; Thompson L; Popat S
    J Thorac Oncol; 2018 Jan; 13(1):63-72. PubMed ID: 28989040
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
    Wang Y; Li RQ; Ai YQ; Zhang J; Zhao PZ; Li YF; He WJ; Xia YX; Li WH
    Clin Transl Oncol; 2015 Sep; 17(9):727-36. PubMed ID: 26041721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor biomarker testing in non-small-cell lung cancer: A decade of change.
    VanderLaan PA; Rangachari D; Majid A; Parikh MS; Gangadharan SP; Kent MS; McDonald DC; Huberman MS; Kobayashi SS; Costa DB
    Lung Cancer; 2018 Feb; 116():90-95. PubMed ID: 29413057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between epidermal growth factor receptor gene mutations and clinicopathological features in patients with non-small cell lung cancer in western Turkey.
    Unal OU; Oztop I; Calibasi G; Baskin Y; Koca D; Demir N; Akman T; Ellidokuz H; Yilmaz AU
    Asian Pac J Cancer Prev; 2013; 14(6):3705-9. PubMed ID: 23886169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose Epidermal Growth Factor Receptor (EGFR)- Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area.
    Hirano R; Uchino J; Ueno M; Fujita M; Watanabe K
    Asian Pac J Cancer Prev; 2016; 17(2):785-9. PubMed ID: 26925681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas.
    Gow CH; Chang HT; Lim CK; Liu CY; Chen JS; Shih JY
    Genes Chromosomes Cancer; 2017 May; 56(5):373-381. PubMed ID: 28063177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
    Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
    Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
    Song Z; Wang X; Zheng Y; Su H; Zhang Y
    Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
    Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
    BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes of thoracic radiotherapy for locally advanced NSCLC with EGFR mutations or EML4-ALK rearrangement.
    Hayashi H; Okamoto I; Kimura H; Sakai K; Nishimura Y; Nishio K; Nakagawa K
    Anticancer Res; 2012 Oct; 32(10):4533-7. PubMed ID: 23060582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consensus recommendations for optimizing biomarker testing to identify and treat advanced
    Cheema PK; Gomes M; Banerji S; Joubert P; Leighl NB; Melosky B; Sheffield BS; Stockley T; Ionescu DN
    Curr Oncol; 2020 Dec; 27(6):321-329. PubMed ID: 33380864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
    Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
    J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors.
    Lin CC; Hsu HH; Sun CT; Shih JY; Lin ZZ; Yu CJ; Chen GG; Hsin MK; Lam KC; Leung L; Yang CH; Mok T
    J Thorac Oncol; 2010 Sep; 5(9):1424-9. PubMed ID: 20631634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.